Riskpilot← Back to searchSign inGet full accessNEDENES APOTEK AS
ASActiveOrg 924630000Natvigveien 1, 4823 NedenesRetail sale of pharmaceutical products · NACE 4773Est. 202011 employees
Revenue 2025
NOK 26,9M
+9% vs 2024
EBITDA margin
6.9%
+38% vs 2024
Equity ratio
6.8%
Financial strength
Net profit 2025
NOK 1,3M
+44% vs 2024
| Revenue | NOK 26,9M | +9% |
| EBITDA | NOK 1,8M | +38% |
| Net profit | NOK 1,3M | +44% |
| Total assets | NOK 5,6M | +22% |
| Equity | NOK 377K | +1153% |
| Employees | 11 | — |
Legal name
NEDENES APOTEK AS
Org number
924630000
Legal form
Aksjeselskap
NACE code
4773 · Retail sale of pharmaceutical products
Founded
28. februar 2020
Share capital
NOK 30 000
Employees
11 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styret i fellesskap.
Company purpose
Eie og drive apotek og handel med apotekvarer.
Address
Natvigveien 1, 4823 Nedenes
Phone
+4737030031
Email
apotek1.nedenes@apotek1.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 14 807 | 18 129 | 21 675 | 24 692 | 26 924 |
| Staff expenses | −2 054 | −2 602 | −2 799 | −3 310 | −3 228 |
| EBITDA | 879 | 913 | 1 319 | 1 339 | 1 848 |
| Depreciation & amort. | −123 | −123 | −123 | −123 | −120 |
| EBIT | 756 | 790 | 1 197 | 1 216 | 1 728 |
| Net financials | −36 | −32 | −27 | −17 | −1 |
| Profit before tax | 721 | 758 | 1 170 | 1 199 | 1 727 |
| Tax | 159 | 167 | 257 | 264 | 380 |
| Net profit | 562 | 591 | 912 | 935 | 1 347 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 4 322 | 6 337 | 4 890 | 4 576 | 5 561 |
| Equity | 791 | 383 | 95 | 30 | 377 |
| Long-term debt | 990 | 523 | 353 | 182 | 0 |
| Short-term debt | 2 541 | 5 431 | 4 442 | 4 364 | 5 179 |
| Total debt | 3 530 | 5 954 | 4 795 | 4 546 | 5 183 |
EBITDA margin
6.9%
This company
15.8%
Market median
-56% vs market
20212025
Equity ratio
6.8%
This company
38.2%
Market median
-82% vs market
20212025
Return on equity
357.2%
This company
18.4%
Market median
+1841% vs market
20212025
Net profit margin
5.0%
This company
8.1%
Market median
-38% vs market
20212025
Asset turnover
4.84×
This company
1.12×
Market median
+332% vs market
20212025
Debt / equity
13.74×
This company
0.62×
Market median
-2116% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MK Chief Executive Officer | Chief Executive Officer | 2024 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Board of Directors | 2021 | |
| Former (1) | ||
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 51% | 51% | 2022 | |
| Company | 24.5% | 24.5% | 2022 | |
| Individual | 24.5% | 24.5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NEDENES APOTEK AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mohamad Karouni | Chief Executive Officer | 0 companies |
| Rabih Karouni | Board of Directors | 0 companies |
| Espen Engelbrethsen | Board of Directors | 0 companies |